Cargando…
Weichang’an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer—Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1
Aim: Angiogenesis plays an important role in the initiation, development, and metastasis of malignant tumors. Antiangiogenic drugs combined with immune therapy are considered to have a synergistic effect on anti-tumor strategy. Weichang’an formula (WCAF) is a prescription of traditional Chinese medi...
Autores principales: | Pan, Chuan-Fang, Zhang, Xi, Wang, Jing-Wen, Yang, Tao, Zhong, Linda L. D., Shen, Ke-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970919/ https://www.ncbi.nlm.nih.gov/pubmed/33746736 http://dx.doi.org/10.3389/fphar.2020.512598 |
Ejemplares similares
-
Identification and Simultaneous Determination of Twelve Active Components in the Methanol Extract of Traditional Medicine Weichang’an Pill by HPLC-DAD-ESI-MS/MS
por: Zhang, Jingze, et al.
Publicado: (2013) -
Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022) -
The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
por: Carvalho, Bruno, et al.
Publicado: (2021) -
Bevacizumab Diminishes Inflammation in an Acute Endotoxin-Induced Uveitis Model
por: Mérida, Salvador, et al.
Publicado: (2018) -
Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
por: Lee, Shu-Ping, et al.
Publicado: (2019)